- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 19.11.24 | Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says | ||
| 19.11.24 | Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer | ||
| 19.11.24 | J&J pill clears skin in two late-stage psoriasis studies | ||
| 19.11.24 | Incyte sinks on setback for drugs acquired in $750M buyout | ||
| 18.11.24 | Syndax secures FDA OK for new kind of leukemia drug | ||
| 18.11.24 | CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest | ||
| 18.11.24 | FDA endorses speedy approval path for Regenxbio Duchenne gene therapy | ||
| 18.11.24 | Reducing variability in gene expression: bottlenecks and solutions | ||
| 18.11.24 | Leveraging NGS to move precision oncology forward, from CDx to commercialization | ||
| 15.11.24 | How a Biogen drug set the stage for a new biotech targeting ALS | ||
| 15.11.24 | 'Find any advantage': 3 biotech leaders on driving R&D success | ||
| 15.11.24 | Surviving in biotech's new normal: 5 tips from industry VCs and CEOs | ||
| 15.11.24 | Halozyme bids for Evotec; BeiGene gets a new name | ||
| 14.11.24 | Trump names RFK Jr. as his pick to lead HHS | ||
| 14.11.24 | Eisai wins over European regulators on Alzheimer's drug Leqembi | ||
| 14.11.24 | PTC wins US approval of gene therapy for fatal enzyme disorder | ||
| 14.11.24 | Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy | ||
| 13.11.24 | Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing | ||
| 13.11.24 | Metsera raises $215M to accelerate obesity drug plans | ||
| 13.11.24 | TRex Bio raises $84M to compete in crowded immune drug field | ||
| 13.11.24 | BioNTech to buy Biotheus, gaining control of cancer bispecific | ||
| 12.11.24 | GSK partners with Flagship startup to hunt for Parkinson's drugs | ||
| 12.11.24 | Biotech investors, including Third Rock, pump $100M into a startup's genetic medicine for ALS | ||
| 12.11.24 | Neurogene hits a setback in the clinic, one week after raising funds | ||
| 12.11.24 | AstraZeneca, Daiichi revise approval plans for Enhertu successor |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
